Russell Investments Group Ltd. trimmed its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 33.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 180,173 shares of the medical instruments supplier’s stock after selling 91,689 shares during the period. Russell Investments Group Ltd.’s holdings in West Pharmaceutical Services were worth $66,844,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. Evergreen Capital Management LLC grew its stake in shares of West Pharmaceutical Services by 2.5% in the third quarter. Evergreen Capital Management LLC now owns 1,131 shares of the medical instruments supplier’s stock worth $419,000 after purchasing an additional 28 shares during the last quarter. Greenleaf Trust increased its holdings in West Pharmaceutical Services by 4.1% during the 2nd quarter. Greenleaf Trust now owns 843 shares of the medical instruments supplier’s stock valued at $303,000 after purchasing an additional 33 shares during the period. Wealth Alliance LLC raised its position in West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock valued at $237,000 after purchasing an additional 35 shares during the last quarter. 55 North Private Wealth LLC raised its position in West Pharmaceutical Services by 5.4% during the 3rd quarter. 55 North Private Wealth LLC now owns 708 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 36 shares during the last quarter. Finally, D.A. Davidson & CO. raised its position in West Pharmaceutical Services by 4.1% during the 3rd quarter. D.A. Davidson & CO. now owns 909 shares of the medical instruments supplier’s stock valued at $337,000 after purchasing an additional 36 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on WST shares. Barclays increased their price objective on West Pharmaceutical Services from $440.00 to $500.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Weiss Ratings raised West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, November 2nd. Zacks Research cut West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Sunday, November 1st. Finally, TD Cowen raised their price target on West Pharmaceutical Services from $420.00 to $500.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Thirteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $424.67.
Check Out Our Latest Research Report on WST
Insider Activity
In other news, VP Annette Favorite sold 8,135 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the completion of the transaction, the vice president owned 16,845 shares in the company, valued at $5,740,944.45. This trade represents a 32.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 15,659 shares of company stock valued at $5,443,749. 0.60% of the stock is currently owned by corporate insiders.
West Pharmaceutical Services Trading Up 1.2%
Shares of NYSE WST traded up $5.04 during midday trading on Friday, hitting $416.34. 479,107 shares of the company traded hands, compared to its average volume of 766,072. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $438.27. The firm has a market cap of $29.00 billion, a P/E ratio of 46.73, a P/E/G ratio of 2.50 and a beta of 1.13. The stock has a 50-day moving average price of $380.32 and a 200 day moving average price of $320.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.10 and a current ratio of 2.82.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical instruments supplier reported $2.66 EPS for the quarter, topping the consensus estimate of $2.20 by $0.46. The business had revenue of $874.50 million during the quarter, compared to analyst estimates of $827.12 million. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. West Pharmaceutical Services’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the business posted $1.96 earnings per share. As a group, analysts expect that West Pharmaceutical Services, Inc. will post 9.46 earnings per share for the current year.
West Pharmaceutical Services Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be given a $0.26 dividend. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 annualized dividend and a dividend yield of 0.2%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s dividend payout ratio is currently 11.67%.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.
Recommended Stories
- Five stocks we like better than West Pharmaceutical Services
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
